DNA Methylation Signatures as Early Epigenetic Biomarkers of Metabolic Risk in Obesity

Authors

  • Nishitha Clamenteen Salins Author
  • Asha Prabhu Author
  • Chethana Y K Author
  • Chaithra D Author
  • Mamatha B V Author

Keywords:

Obesity, DNA Methylation, Epigenetic Biomarkers, metabolic Risk, Insulin Resistance, Epigenetics

Abstract

Obesity is a multifactorial metabolic disorder influenced by genetic, environmental, and lifestyle factors, raising the chance of developing type 2 diabetes (T2D), cardiovascular diseases, and metabolic syndrome. DNA methylation, in particular, is one of the epigenetic mechanisms that play an important role in linking environmental exposures to changed expression of genes and metabolic dysfunction. This mini‑review highlights DNA methylation's potential signatures as early biomarkers of metabolic risk in obesity. DNA methylation is the addition of methyl groups to cytosine residues, altering gene expression without changing the DNA sequence. Altered methylation patterns in genes such as Leptin (LEP), Adiponectin (ADIPOQ), Proopiomelanocortin (POMC), Neuropeptide Y (NPY), Peroxisome Gamma Coactivator 1‑Alpha (PGC1A), and Hypoxia Inducible Factor 3 Subunit Alpha (HIF3A) have been linked to insulin resistance, obesity, energy imbalance, and inflammation. These changes may help identify individuals at risk of developing obesity‑related metabolic complications. Furthermore, DNA methylation is potentially reversible and can be influenced by dietary modifications, physical activity, and weight reduction, making it a promising target for preventive and personalised interventions. However, tissue‑specific variations and differences in study populations remain challenges. Additional long‑term research is needed to validate reliable DNA methylation signatures and establish their clinical utility in early metabolic risk prediction and personalised obesity management.

References

1. Samblas M, Milagro FI, Martínez A. DNA methylation markers in obesity, metabolic syndrome, and weight loss. Epigenetics. 2019;14(5):421-444. doi:10.1080/15592294.2019.

2. Biddle SJH, Bengoechea Garcia E, Pedisic Z, et al. Screen time, other sedentary behaviours, and obesity risk in adults: a review of reviews. Curr Obes Rep. 2017;6:134–147.

3. St-Onge MP. Sleep-obesity relation: underlying mechanisms and consequences for treatment. Obes Rev. 2017;18:34–39.

4. Kim TJ, Roesler NM, von Dem Knesebeck O. Causation or selection – examining the relation between education and overweight/obesity in prospective observational studies: a meta-analysis. Obes Rev. 2017;18:660–672.

5. Weaver J. Classical endocrine diseases causing obesity. Front Horm Res. 2007;36:212–228.

6. Martínez de Morentin-Aldabe BE, Hernández-Ruiz de Eguilaz M, Pérez-Díez S, et al. Influence of psychotropic drugs prescription on body weight increase. Rev Esp Nutr Hum Diet. 2013;17:17–26.

7. Singh RK, Kumar P, Mahalingam K. Molecular genetics of human obesity: a comprehensive review. Comptes Rendus - Biol. 2017;340:87–108.

8. Mahmoud AM. An Overview of Epigenetics in Obesity: The Role of Lifestyle and Therapeutic Interventions. Int J Mol Sci. 2022;23(3):1341. doi:10.3390/ijms23031341.

9. Campion J, Milagro FI, Martinez JA. Individuality and epigenetics in obesity. Obes Rev. 2009;10:383–392.

10. Huang Q, Ma C, Chen L, et al. Mechanistic insights into the interaction between transcription factors and epigenetic modifications and the contribution to the development of obesity. Front Endocrinol. 2018;9:370.

11. Dupont C, Armant DR, Brenner CA. Epigenetics: definition, mechanisms and clinical perspective. Semin Reprod Med. 2009;27:351–357.

12. Weinhold B. Epigenetics: The science of change. Environ Health Perspect. 2006;114:A160–A167. doi:10.1289/ehp.114-a160.

13. Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009;462:315–322.

14. Smith ZD, Meissner A. DNA methylation: roles in mammalian development. Nat Rev Genet. 2013;14:204–220.

15. Turcot V, Tchernof A, Deshaies Y, et al. LINE-1 methylation in visceral adipose tissue of severely obese individuals is associated with metabolic syndrome status and related phenotypes. Clin Epigenet. 2012;4:10. doi:10.1186/1868-7083-4-10.

16. Petrus P, Bialesova L, Checa A, et al. Adipocyte Expression of SLC19A1 Links DNA Hypermethylation to Adipose Tissue Inflammation and Insulin Resistance. J Clin Endocrinol Metab. 2018;103:710–721. doi:10.1210/jc.2017-01382.

17. Kuroda A, Rauch TA, Todorov I, et al. Insulin gene expression is regulated by DNA methylation. PLoS ONE. 2009;4:e6953. doi:10.1371/annotation/947a8d4a-3585-4b23-ac84-b47a255a70d9.

18. Nilsson E, Jansson PA, Perfilyev A, et al. Altered DNA methylation and differential expression of genes influencing metabolism and inflammation in adipose tissue from subjects with type 2 diabetes. Diabetes. 2014;63:2962–2976. doi:10.2337/db13-1459.

19. Pinhel MAS, Noronha NY, Nicoletti CF, et al. Changes in DNA Methylation and Gene Expression of Insulin and Obesity-Related Gene PIK3R1 after Roux-en-Y Gastric Bypass. Int J Mol Sci. 2020;21:4476. doi:10.3390/ijms21124476.

20. Gemma C, Sookoian S, Alvarinas J, et al. Maternal pregestational BMI is associated with methylation of the PPARGC1A promoter in newborns. Obesity. 2009;17:1032–1039. doi:10.1038/oby.2008.605.

21. Brons C, Jacobsen S, Nilsson E, et al. Deoxyribonucleic acid methylation and gene expression of PPARGC1A in human muscle is influenced by high-fat overfeeding in a birth-weight-dependent manner. J Clin Endocrinol Metab. 2010;95:3048–3056. doi:10.1210/jc.2009-2413.

22. Perkins E, Murphy SK, Murtha AP, et al. Insulin-like growth factor 2/H19 methylation at birth and risk of overweight and obesity in children. J Pediatr. 2012;161:31–39. doi:10.1016/j.jpeds.2012.01.015.

23. Dick KJ, Nelson CP, Tsaprouni L, et al. DNA methylation and body-mass index: A genome-wide analysis. Lancet. 2014;383:1990–1998. doi:10.1016/S0140-6736(13)62674-4.

24. Pan H, Lin X, Wu Y, et al. HIF3A association with adiposity: The story begins before birth. Epigenomics. 2015;7:937–950. doi:10.2217/epi.15.45.

25. Heikkinen A, Bollepalli S, Ollikainen M. The potential of DNA methylation as a biomarker for obesity and smoking. J Intern Med. 2022;292(3):390-408. doi:10.1111/joim.13496.

Downloads

Published

2026-11-20

How to Cite

DNA Methylation Signatures as Early Epigenetic Biomarkers of Metabolic Risk in Obesity. (2026). Indo-American Journal of Life Sciences and Biotechnology, 23(04), 11-17. https://iajlb.org/index.php/iajlb/article/view/269

Similar Articles

41-50 of 60

You may also start an advanced similarity search for this article.